Type characterisation and antibiotic susceptibility of Burkholderia (Pseudomonas) cepacia isolates from patients with cystic fibrosis in the United Kingdom and the Republic of Ireland

Journal of Medical Microbiology

Volumn 44, Issue 3, 1996, Pages 203-210

  Pitt, T L ^a   Kaufmann, Mary E ^a   Patel, P S ^a   Benge, Louise C A ^a   Gaskin, Sophie ^a   Livermore, D M ^b  

^a CENTRAL PUBLIC HEALTH LABORATORY   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; BIAPENEM; CARBENICILLIN; CEFOTAXIME; CEFTAZIDIME; CEFUROXIME; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN; SULFAMETHOXAZOLE; TAZOBACTAM; TETRACYCLINE; TOBRAMYCIN; TRIMETHOPRIM;

ANTIBIOTIC RESISTANCE; ARTICLE; BURKHOLDERIA CEPACIA; CYSTIC FIBROSIS; GRAM NEGATIVE INFECTION; HUMAN; IRELAND; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; UNITED KINGDOM;

EID: 0029992001     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/00222615-44-3-203     Document Type: Article

References (37)

1. Yabuuchi E, Kosako Y, Oyaizu H et al. Proposal of Burkholderia gen.nov. and transfer of seven species of the genus Pseudomonas homology group II to the new genus, with the type species Burkholderia cepacia (Palleroni and Holmes 1981) comb. nov. Microbiol Immunol 1992; 36: 1251-1275.
2. Burkholder WH. Sour skin: a bacterial rot of onion bulbs. Phytopathol 1950; 40: 115-117.
3. Martone WJ, Tablan OC, Jarvis WR. The epidemiology of nosocomial epidemic Pseudomonas cepacia infections. Eur J Epidemiol 1987; 3: 222-232.
4. Isles A, Maclusky I, Corey M et al. Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr 1984; 104: 206-210.
5. Thomassen MJ, Demko CA, Klinger JD, Stern RC. Pseudomonas cepacia colonization among patients with cystic fibrosis. A new opportunist. Am Rev Respir Dis 1985; 131: 791-796.
6. Gladman G, Connor PJ, Williams RF, David TJ. Controlled study of Pseudomonas cepacia and Pseudomonas maltophilia in cystic fibrosis. Arch Dis Child 1992; 67: 192-195.
7. Walters S, Smith EG. Pseudomonas cepacia in cystic fibrosis: transmissibility and its implications. Lancet 1993; 342: 3-4.
8. Nelson JW, Doherty CJ, Brown PH, Greening AP, Kaufmann ME, Govan JRW. Pseudomonas cepacia in inpatients with cystic fibrosis. Lancet 1991; 338: 1525.
9. Millar-Jones L, Paull A, Saunders Z, Goodchild MC. Transmission of Pseudomonas cepacia among cystic fibrosis patients. Lancet 1992; 340: 491.
10. Govan JRW, Brown PH, Maddison J et al. Evidence for transmission of Pseudumonas cepacia by social contact in cystic fibrosis. Lancet 1993; 342: 15-19.
11. Corkill JE, Sisson PR, Smyth A et al. Application of pyrolysis mass spectroscopy and SDS-PAGE in the study of the epidemiology of Pseudomonas cepacia in cystic fibrosis. J Med Microbiol 1994; 41: 106-111.
12. LiPuma JJ, Mortensen JE, Dasen SE et al. Ribotype analysis of Pseudumonas cepacia from cystic fibrosis treatment centers. J Pediatr 1988; 113: 859-863.
13. Anderson DJ, Kuhns JS, Vasil ML, Gerding DN, Janoff EN. DNA fingerprinting by pulsed field electrophoresis and ribotyping to distinguish Pseudomonas cepacia isolates from a nosocomial outbreak. J Clin Microbiol 1991; 29: 648-649.
14. Barrow GI, Feltham RKA (eds). Cowan and Steel's Manual for the identification of medical bacteria, 3rd edn. Cambridge, Cambridge University Press. 1993: 30-31.
15. Pitcher DG, Saunders NA, Owen RJ. Rapid extraction of bacterial genomic DNA with guanidium thiocyanate. Lett Appl Microbiol 1989; 8: 151-156.
16. Garaizar J, Kaufmann ME, Pitt TL. Comparison of ribotyping with conventional methods for the type identification of Enterobacter cloacae. J Clin Microbiol 1991; 29: 1303-1307.
17. Grothues D, Koopmann U, von der Hardt H, Tümmler B. Genome fingerprinting of Pseudomonas aeruginosa indicates colonization of cystic fibrosis siblings with closely related strains. J Clin Microbiol 1988; 26: 1973-1977.
18. Dice LR. Measures of the amount of ecologic association between species. Ecology 1945; 26: 297-302.
19. Donnelly JP. Limitations of box-plots in summarizing MIC data. J Antimicrob Chemother 1994; 33: 1251.
20. Shannon K. Limitations of box-plots in summarizing MIC data: reply. J Antimicrob Chemother 1994; 33: 1252.
21. LiPuma J, Dasen SE, Neilson DW, Stern RC, Stull TL. Person-to-person transmission of Pseudomonas cepacia between patients with cystic fibrosis. Lancet 1990; 336: 1094-1096.
22. Steinbach S, Sun L, Jiang RZ et al. Transmissibility of Pseudomonas cepacia infection in clinic patients and lung-transplant recipients with cystic fibrosis. N Engl J Med 1994; 331: 981-987.
23. Johnson WM, Tyler SD, Rozee KR. Linkage analysis of geographic and clinical clusters in Pseudomonas cepacia infections by multilocus enzyme electrophoresis and ribotyping. J Clin Microbiol 1994; 32: 924-930.
24. Smith DL, Gumery LB, Smith EG, Stableforth DE, Kaufmann ME, Pitt TL. Epidemic of Pseudomonas cepacia in an adult cystic fibrosis: evidence of person-to-person transmission. J Clin Microbiol 1993; 31: 3017-3022.
25. Simpson IN, Finlay J, Winstanley DJ et al. Multi-resistance isolates possessing characteristics of both Burkholderia (Pseudomonas) cepacia and Burkholderia gladioli from patients with cystic fibrosis. J Antimicrob Chemother 1994; 34: 353-361.
26. Nelson JW, Butler SL, Krieg D, Govan JRW. Virulence factors of Burkholderia cepacia. FEMS Immunol Med Microbiol 1994; 8: 89-98.
27. Butler SL, Nelson JW, Govan JRW. Cell surface characteristics of Pseudomonas cepacia isolates from patients with cystic fibrosis. XI International CF Congress, Dublin 1992. Abstract TP8.
28. Scordilis GL, Ree H, Lessie TG. Identification of transposable elements which activate gene expression in Pseudomonas cepacia. J Bacteriol 1987; 169: 8-13.
29. Yohalem DS, Lorbeer JW. Multilocus isoenzyme diversity among strains of Pseudomonas cepacia isolated from decayed onions, soils and clinical sources. System Appl Microbiol 1994; 17: 116-124.
30. LiPuma JJ, Fisher MC, Dasen SE, Mortensen JE, Stull TL. Ribotype stability of serial pulmonary isolates of Pseudomonas cepacia. J Infect Dis 1991; 164: 133-136.
31. Working Party on Antibiotic Sensitivity Testing of the British Society for Antimicrobial Chemotherapy. A guide to sensitivity testing. J Antimicrob Chemother 1991; 27 Suppl D: 1-50.
32. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 3rd edn. Document LM7-A3 1993; 13 No. 25. Villanova, PA, National Committee for Clinical Laboratory Standards. 1993.
33. Muller-Serieys C, De Larminat V, Monteil H, Bergogne-Berezin E, Jehl H. Bronchial penetration of piperacillin-tazobactam (Pip-tz) in intensive care patients: a multiple dose study. Program and Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy 1993; Abstract no. 253.
34. Strandvik B, Malmborg A-S, Alfredson H, Ericsson A. Clinical results and pharmacokinetics of ceftazidime treatment in patients with cystic fibrosis. J Antimicrob Chemother 1983; 12 Suppl A: 283-287.
35. Gold R, Jin E, Levison A, Isles A, Fleming PC. Ceftazidime alone and in combination in patients with cystic fibrosis: lack of efficacy in treatment of severe respiratory infections caused by Pseudomonas cepacia. J Antimicrob Chemother 1983; 12 Suppl A: 331-336.
36. Lewin C, Doherty C, Govan J. In vitro activities of meropenem, PD 127391, PD 131628, ceftazidime, chloram-phenicol, co-trimaxazole, and ciprofloxacin against Pseudomonas cepacia. Antimicrob Agents Chemother 1993; 37: 123-125.
37. 2 on in vitro susceptibility of Pseudomonas cepacia to β-lactams. Pediatr Res 1994; 35: 299-302.